Edition:
India

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

16.39USD
13 Aug 2018
Change (% chg)

-- (--)
Prev Close
$16.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
63,774
52-wk High
$30.70
52-wk Low
$13.58

Chart for

About

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $347.34
Shares Outstanding(Mil.): 22.69
Dividend: --
Yield (%): --

Financials

BRIEF-Concert Pharmaceuticals Reports Q1 Loss Per Share $0.19

* CONCERT PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

03 May 2018

BRIEF-Concert Pharmaceuticals Completes Enrollment In Phase 2A Trial Of CTP-543 In Alopecia Areata

* CONCERT PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 2A TRIAL OF CTP-543 IN ALOPECIA AREATA

25 Apr 2018

BRIEF-Concert Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $250.0 Million - SEC Filing

* CONCERT PHARMACEUTICALS INC FILES FOR MIXED SHELF OFFERING OF UP TO $250.0 MILLION - SEC FILING Source text (http://bit.ly/2t6Qumw) Further company coverage: (Reuters.Brief@thomsonreuters.com)

01 Mar 2018

BRIEF-Concert Pharmaceuticals Reports Qtrly Loss Per Share $0.26

* CONCERT PHARMACEUTICALS REPORTS YEAR ENDED 2017 FINANCIAL RESULTS

01 Mar 2018

BRIEF-Concert Pharma Says Intends To Complete Evaluation And Advance CTP-692 Into Clinical Development By 2018 End

* CONCERT PHARMACEUTICALS INC SAYS INTENDS TO COMPLETE PRECLINICAL EVALUATION AND ADVANCE CTP-692 INTO CLINICAL DEVELOPMENT BY YEAR-END 2018 Source text for Eikon: Further company coverage:

01 Mar 2018

Earnings vs. Estimates